Literature DB >> 15142885

Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery.

Joost A van Hilten1, Leo M G van de Watering, J Hajo van Bockel, Cornelis J H van de Velde, Job Kievit, Ronald Brand, Wilbert B van den Hout, Robert H Geelkerken, Rudi M H Roumen, Ronald M J Wesselink, Ankie W M M Koopman-van Gemert, Jan Koning, Anneke Brand.   

Abstract

OBJECTIVE: To compare postoperative complications in patients undergoing major surgery who received non-filtered or filtered red blood cell transfusions.
DESIGN: Prospective, randomised, double blinded trial.
SETTING: 19 hospitals throughout the Netherlands (three university; 10 clinical; six general). PARTICIPANTS: 1051 evaluable patients: 79 patients with ruptured aneurysm, 412 patients undergoing elective surgery for aneurysm, and 560 undergoing gastrointestinal surgery.
INTERVENTIONS: The non-filtered products had the buffy coat removed and were plasma reduced. The filtered products had the buffy coat removed, were plasma reduced, and filtered before storage to remove leucocytes. MAIN OUTCOME MEASURES: Mortality and duration of stay in intensive care. Secondary end points were occurrence of multi-organ failure, infections, and length of hospital stay.
RESULTS: No significant differences were found in mortality (odds ratio for filtered v non-filtered 0.80, 95% confidence interval 0.53 to 1.21) and in mean stay in intensive care (- 0.4 day, - 1.6 to 0.6 day). In the filtered group the mean length of hospital stay was 2.4 days shorter (- 4.8 to 0.0 day; P = 0.050) and the incidence of multi-organ failure was 30% lower (odds ratio 0.70, 0.49 to 1.00; P = 0.050). There were no differences in rates of infection (0.98, 0.73 to 1.32).
CONCLUSION: The use of filtered transfusions in some types of major surgery may reduce the length of hospital stay and the incidence of postoperative multi-organ failure.

Entities:  

Mesh:

Year:  2004        PMID: 15142885      PMCID: PMC420164          DOI: 10.1136/bmj.38103.735266.55

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  29 in total

1.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

Review 2.  Leukocyte-reduced blood transfusions: perioperative indications, adverse effects, and cost analysis.

Authors:  A D Sharma; G Sreeram; T Erb; H P Grocott; T F Slaughter
Journal:  Anesth Analg       Date:  2000-06       Impact factor: 5.108

Review 3.  Multicenter randomized controlled trials in transfusion medicine.

Authors:  E C Vamvakas
Journal:  Transfus Med Rev       Date:  2000-04

Review 4.  Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?

Authors:  E C Vamvakas; M A Blajchman
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

Review 5.  Mechanisms of the systemic inflammatory response.

Authors:  G Asimakopoulos
Journal:  Perfusion       Date:  1999-07       Impact factor: 1.972

6.  Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?

Authors:  P C Hébert; E Yetisir; C Martin; M A Blajchman; G Wells; J Marshall; M Tweeddale; G Pagliarello; I Schweitzer
Journal:  Crit Care Med       Date:  2001-02       Impact factor: 7.598

7.  Subgroup analysis and other (mis)uses of baseline data in clinical trials.

Authors:  S F Assmann; S J Pocock; L E Enos; L E Kasten
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

8.  Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial.

Authors:  A C Collier; L A Kalish; M P Busch; T Gernsheimer; S F Assmann; T A Lane; D M Asmuth; M M Lederman; E L Murphy; P Kumar; M Kelley; T P Flanigan; D K McMahon; H S Sacks; M S Kennedy; P V Holland
Journal:  JAMA       Date:  2001-03-28       Impact factor: 56.272

9.  Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications. Results of a double-blinded, randomized study.

Authors:  I L Titlestad; L S Ebbesen; A P Ainsworth; S T Lillevang; N Qvist; J Georgsen
Journal:  Int J Colorectal Dis       Date:  2001-06       Impact factor: 2.571

10.  Leukocyte-reduced transfusions in cardiac surgery results of an implementation trial.

Authors:  Neil Blumberg; Joanna M Heal; Judith W Cowles; George L Hicks; William H Risher; Prem K Samuel; Scott A Kirkley
Journal:  Am J Clin Pathol       Date:  2002-09       Impact factor: 2.493

View more
  23 in total

Review 1.  Leucoreduction of blood components: an effective way to increase blood safety?

Authors:  Maria Bianchi; Stefania Vaglio; Simonetta Pupella; Giuseppe Marano; Giuseppina Facco; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-12-16       Impact factor: 3.443

Review 2.  Critical care issues in the early management of severe trauma.

Authors:  Alberto Garcia
Journal:  Surg Clin North Am       Date:  2006-12       Impact factor: 2.741

3.  New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells.

Authors:  Katie Grimshaw; Julie Sahler; Sherry L Spinelli; Richard P Phipps; Neil Blumberg
Journal:  Transfusion       Date:  2011-04       Impact factor: 3.157

4.  Perioperative transfusion for pancreaticoduodenectomy and its impact on prognosis in resected pancreatic ductal adenocarcinoma.

Authors:  E Clark; S Connor; M A Taylor; C L Hendry; K K Madhavan; O J Garden; R W Parks
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

5.  Blood Transfusions Correct Anemia and Improve Tissue Oxygenation in Surgical and Critically ill Patients.

Authors:  Can İnce
Journal:  Turk J Anaesthesiol Reanim       Date:  2017-02-01

6.  Effect of storage period of red blood cell suspensions on helper T-cell subpopulations.

Authors:  Salih H Bal; Yasemin Heper; Levent T Kumaş; Furkan Guvenc; Ferah Budak; Güher Göral; Haluk B Oral
Journal:  Blood Transfus       Date:  2017-03-15       Impact factor: 3.443

7.  Comment on Debate: Blood is Friend or/and Foe?

Authors:  M S Raghuraman
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-02-01

8.  Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer.

Authors:  Mitsuro Kanda; Daisuke Kobayashi; Chie Tanaka; Naoki Iwata; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Shuji Nomoto; Kenta Murotani; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2015-01-07       Impact factor: 7.370

9.  The abandoned controversy surrounding universal white blood cell reduction.

Authors:  Eleftherios C Vamvakas
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

10.  Cost-effectiveness of leucoreduction for prevention of febrile non-haemolytic transfusion reactions.

Authors:  Argirios E Tsantes; Elias Kyriakou; Georgios K Nikolopoulos; Dimitrios Stylos; Marlene Sidhom; Stefanos Bonovas; Panagiota Douramani; Dimitrios Kalantzis; Styliani Kokoris; Serena Valsami; Konstantinos Stamoulis; Marianna Politou; Leontini Foudoulaki-Paparizos
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.